You are here Home Guidance and resources Publications hub Scheduling decisions (final) Scheduling delegate's final decisions, January 2017 Summary of delegates' final decisions Scheduling medicines and poisons Last updated 16 January 2017 Listen Print Share Loading... Final decisions on matters not referred to an expert advisory committee 2. New Chemical Entities – medicines for human therapeutic useSummary of delegates' final decisionsSubstanceSubstance Final decisionOcrelizumab Schedule 4 – New EntryOCRELIZUMAB.Implementation date: 1 February 2017Eluxadoline Schedule 4 – New EntryELUXADOLINE.Implementation date: 1 February 2017Cobimetinib Schedule 4 – New EntryCOBIMETINIB.Implementation date: 1 February 2017Lenvatinib Schedule 4 – New EntryLENVATINIB.Implementation date: 1 February 2017Talimogene laherparepvec Schedule 4 – New EntryTALIMOGENE LAHERPAREPVEC.Implementation date: 1 February 2017Dermatophagoides pteronyssinus and Dermatophagoides farinae extract Schedule 4 – New EntryDERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE EXTRACT.Implementation date: 1 February 2017Fomepizole Schedule 4 – New EntryFOMEPIZOLE.Implementation date: 1 February 2017Sarilumab Schedule 4 – New EntrySARILUMAB.Implementation date: 1 February 2017Osimertinib Schedule 4 – New EntryOSIMERTINIB.Implementation date: 1 February 2017Lipegfilgrastim Schedule 4 – New EntryLIPEGFILGRASTIM.Implementation date: 1 February 2017Elotuzumab Schedule 4 – New EntryELOTUZUMAB.Implementation date: 1 February 2017Ixazomib Schedule 4 – New EntryIXAZOMIB.Implementation date: 1 February 2017Lumacaftor Schedule 4 – New EntryLUMACAFTOR.Implementation date: 1 February 2017Sodium zirconium cyclosilicate Schedule 4 – New EntrySODIUM ZIRCONIUM CYCLOSILICATE.Implementation date: 1 February 2017Sonidegib Schedule 4 – New EntrySONIDEGIB.Implementation date: 1 February 2017Venetoclax Schedule 4 – New EntryVENETOCLAX.Implementation date: 1 February 2017Carfilzomib Schedule 4 – New EntryCARFILZOMIB.Implementation date: 1 February 2017 Previous 1.4. 2,4-Diaminophenoxyethanol hydrochloride Next 2.1. Ocrelizumab